Hillevax Inc (HLVX) - News Archive

HilleVax Inc Faces Tumultuous Waters: 2024 Struggles Amid Norovirus Vaccine Setbacks and Workforce Reductions In an unforgiving landscape fueled by rigorous competition and increasing economic pressures, HilleVax Inc. (...

BOSTON, July 31, 2024 - HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative vaccines, has revealed plans to downsize its workforce in a bid...

Over the past quarter, Hillevax Inc (NASDAQ: HLVX) has found its shares trailing significantly behind the overall market performance. With a staggering drop of approximately 86.93% over the last four weeks, it seems the...

In recent weeks, HilleVax Inc. (NASDAQ: HLVX) has found itself at the center of a tumultuous landscape, marked by regulatory scrutiny, disappointing clinical trial results, and notable shifts in investor sentiment. This...

HilleVax Inc, a pharmaceutical company specializing in vaccine development, has recently experienced a significant decline in their share performance. This decline can be attributed to multiple factors, including the ha...

The NEST-IN1 Phase 2b Clinical Study conducted by HilleVax aimed to assess the efficacy of HIL-214 in infants. However, disappointing results have led the company to discontinue the drug s further development in this sp...

The ever-prevalent norovirus, notorious for wreaking havoc on our gastrointestinal system, may soon meet its match. HilleVax and Kangh s recent exclusive license agreement for the Hexavalent VLP Norovirus Vaccine Candid...

HilleVax, a Promising Player in the Biopharmaceutical Industry, Seeks to Raise $100 Million in an Underwritten Public OfferingBoston, September 19, 2023 - HilleVax, Inc. (Nasdaq: HLVX), a distinguished clinical-stage bi...